Evidence map›Paper›PMID 25211438›Full record

ArticleAIDS (London, England)2014

Tuberculosis distorts the inhibitory impact of interleukin-10 in HIV infection.

Shivan Chetty, Filippos Porichis, Pamla Govender, Jennifer Zupkosky, Musie Ghebremichael, Mona Pillay, Bruce D Walker, Thumbi Ndung'u, Daniel E Kaufmann, Victoria O Kasprowicz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Shivan ChettyaHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal bKwaZulu-Natal Research Institute for TB and HIV (K-RITH), KwaZulu-Natal, Durban, South Africa cThe Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts dHoward Hughes Medical Institute, Chevy Chase, Maryland eDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA fCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada gDivision of Medical Virology, University of Cape Town, Cape Town, South Africa. *Shivan Chetty and Filippos Porichis contributed equally to the writing of this article.
Filippos Porichis
Pamla Govender
Jennifer Zupkosky
Musie Ghebremichael
Mona Pillay
Bruce D Walker
Thumbi Ndung'u
Daniel E Kaufmann
Victoria O Kasprowicz
Ragon Institute of MGH, MIT and Harvard · USUniversity of KwaZulu-Natal · ZAMassachusetts General Hospital · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Targeting the PD-1 signaling pathway to rescue HIV T cell dysfunctionP01AI080192 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2008 to 2012
$12.6M
Immunoregulatory networks and HIV pathogenesisR01HL092565 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KAUFMANN, DANIEL E · 2007 to 2015
$3.4M
NHLBI NIH HHS R01 HL-092565NHLBI NIH HHS R01 HL092565NIAID NIH HHS P01 AI-080192NIAID NIH HHS P01 AI080192NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

objectivesThis study aimed to assess how Mycobacterium tuberculosis (MTB) coinfection alters the impact of interleukin-10 in chronic HIV infection.

designWe assessed plasma cytokine levels (interleukin-10, interferon-γ, tumor necrosis factor-α, interleukin-2, interleukin-6 and interleukin-13) in 82 individuals presenting with HIV monoinfection, HIV-LTBI (latent MTB infection) coinfection or HIV-TB (active tuberculosis) coinfection. We also assessed the influence of MTB on the functional impact of interleukin-10 receptor alpha (interleukin-10Rα) blockade on HIV and MTB-specific CD4(+) T cells.

methodsPlasma cytokine levels were measured by high sensitivity Luminex. We used an ex-vivo interleukin-10Rα blockade assay to assess if functional enhancement of HIV and MTB-specific CD4(+) T cells was possible following a 48-h stimulation with HIV gag or pooled ESAT-6 (6 kDa early secretory antigenic target) and CFP-10 (10-kDa culture filtrate protein) peptides. Cell supernatant was collected 48 h after stimulation and the cytokine profile was measured by Luminex.

resultsPlasma interleukin-10 levels were elevated in HIV-TB as compared with HIV monoinfection (P < 0.05) and HIV-LTBI (P < 0.05). Plasma interleukin-10 levels correlated to HIV viral load in HIV monoinfection (P = 0.016) and HIV-LTBI (P = 0.042), but not HIV-TB. Ex-vivo blockade of interleukin-10Rα significantly enhanced MTB and HIV-specific CD4(+) T-cell function in HIV-LTBI individuals but not in HIV-TB individuals.

conclusionTuberculosis disrupts the correlation between interleukin-10 and markers of HIV disease progression. In addition, HIV-TB is associated with a more inflammatory cytokine milieu compared with HIV monoinfection. Interestingly, interleukin-10Rα blockade can enhance both HIV and MTB-specific T-cell function in HIV-LTBI, but not in HIV-TB coinfection.

Indexed as

CD4-Positive T-LymphocytesHIV InfectionsHumansInterleukin-10Mycobacterium tuberculosisTuberculosisInterleukin-10

Identifiers

PMID25211438
PMCPMC4381538
OpenAlexW2326961883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.